Immuneering Corporation (IMRX) fundamentals score
Immuneering is a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive . It is developing and seeking to commercialize an entirely new category of anti-cancer medicines, Deep Cyclic Inhibitors, which it believes have the potential to be more effective and better tolerated targeted therapies.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 3.2 out of 10, Unhealthy fundamentals
- Growth: 3.3/10
- Profitability: 1.0/10
- Financial health: 5.4/10
- Earnings quality: 5.4/10
- Valuation: 1.5/10
Scores are calculated from Immuneering Corporation’s SEC filings, using the 12 months through 2023-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10